On Monday, Harmony Biosciences earned a positive adjustment to its Relative Strength (RS) Rating, from 69 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 as they begin their largest climbs. See if Harmony Biosciences can continue to show renewed price strength and hit that benchmark.
Harmony Biosciences is building a consolidation with a 41.61 entry. See if the stock can clear the breakout price in heavy volume.
The company reported 17% earnings growth in its most recent report, while sales growth came in at 19%.
The company earns the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
